02345nas a2200217 4500008004100000245010900041210007100150260001800221300001200239490000600251520163900257653002201896653002501918653001301943653001701956653002101973100001801994700002702012700002702039856006102066 2017 eng d00aAntihyperglycemic Potential of Saponin‑enriched Fraction from Pithecellobium dulce Benth. Seed Extract0 aAntihyperglycemic Potential of Saponin‑enriched Fraction from Pi cDecember 2017 as23-s260 v93 a

Background: Indian traditional system of medicine uses Pithecellobium dulce for the treatment of diabetes mellitus. Objectives: This study aims to develop an extract rich in saponins derived from seeds of the plant and to evaluate its antihyperglycemic potential in vitro and in vivo. Materials and Methods: Defatted seeds were extracted with methanol and processed to afford saponin‑enriched fraction (Pithecellobium dulce saponin‑enriched fraction [PDSEF]). This fraction was evaluated for its potential to inhibit enzymes such as α‑glucosidase and α‑amylase, in vitro. The fraction was subjected to oral toxicity study followed by in vivo sucrose tolerance test. An analytical high‑performance liquid chromatography method was developed for fingerprinting of the fraction. Results: The method adopted for enrichment of saponins was robust enough to enrich saponin content to 96.37% ±1.21% w/w. PDSEF displayed superior inhibition of enzymes (α‑glucosidase and α‑amylase with IC50 of 5.12 ± 0.15 µg/ml and 17.28 ± 0.23 µg/ml, respectively) compared to acarbose. It was found to be safe in mice up to 2000 mg/kg and significantly prevented blood glucose level in sucrose tolerance test by inhibiting enzymes responsible for hydrolysis of sucrose. Conclusion: PDSEF displayed excellent antihyperglycemic activity in vitro and in vivo and should be evaluated further to develop it as a promising drug for the management of diabetes mellitus.

10aAntihyperglycemic10aPithecellobium dulce10asaponins10aα‑amylase10aα‑glucosidase1 aKumar, Mahesh1 aGovindrajan, Jeyabalan1 aNyola, Narendra, Kumar uhttps://www.phcogres.com/article/2017/9/5/104103prpr1817